IR-Med Inc.

Equities

IRME

US46265R1032

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets Other stock markets 09:30:18 2024-05-30 am EDT			5-day change	1st Jan Change
1 ^USD	+31.58%		+66.67%	-13.04%

May. 22	IR-Med Inc.?s PressureSafe Reduced Pressure Injuries by 50% During a Usability Study with Clalit, Israel?s Hmo	CI
May. 13	IR-Med Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

IR-Med Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 16, 2022 at 09:25 am EDT

IR-Med Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 0.849 million compared to USD 0.444 million a year ago. Basic loss per share from continuing operations was USD 0.013 compared to USD 0.007 a year ago.

Latest news about IR-Med Inc.

IR-Med Inc.?s PressureSafe Reduced Pressure Injuries by 50% During a Usability Study with Clalit, Israel?s Hmo	May. 22	CI
IR-Med Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
IR-Med Inc.'S PressureSafe Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries	Apr. 05	CI
IR-Med Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
IR-Med Inc. and I.R Med Ltd. Appoints Aharon Klein as Interim Chief Executive Officer	Mar. 05	CI
IR-Med Inc. Announces Cessation of Tzur Di-Cori Pursuant as Chief Executive Officer	Feb. 28	CI
IR-Med Inc. Announces Resignation of Inna Martin as Director	Feb. 23	CI
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe? Device at NPIAP 2024 Annual Conference on February 16	Feb. 13	CI
IR-Med Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
IR-MED Announces Executive Changes Effective as of October 15, 2023	23-10-04	CI
Ir-Med to Conduct Usability Study with Methodist Healthcare of San Antonio for Its Pressuresafe Device Which Is Slated for U.S. Launch in H1 2024	23-09-26	CI
IR-Med Inc. Appoints Richard Serbin, Esq. to Its Advisory Board	23-09-13	CI
IR-Med Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Ir-Med Inc. Announces Interim Results from A Clinical Study of Pressuresafe	23-07-17	CI
IR-Med Inc. Appoints Lynn Eschenbacher to its Advisory Board	23-06-07	CI
IR-Med Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
IR-Med Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
IR-Med Inc. Auditor Raises 'Going Concern' Doubt	23-03-28	CI
IR-Med Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
IR-Med Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
IR-Med Inc. announced that it has received $0.425002 million in funding	22-07-30	CI
IR-Med, Inc. Announces Resignation of David Lazar to Its Board of Directors	22-07-01	CI
IR-Med Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
IR-Med Announces Appointment of Moshe Gerber as Chief Executive Officer	22-05-10	CI
IR-Med Inc. Announces Resignation of Rom Eliaz as Chief Executive Officer	22-04-29	CI

Chart IR-Med Inc.

Duration

Period

More charts

Company Profile

IR-Med, Inc. is a development-stage medical device company. The Company is engaged in developing its technology through its subsidiary and is utilizing Infra-Red-light spectroscopy (IR) combined with artificial intelligence (AI) technology platform to develop non-invasive devices for various medical indications, by detecting and measuring various biomarkers and molecules in the blood and in human tissue in real-time. The Company has three principal medical devices in development. Its product under development, PressureSafe, is a handheld optical monitoring device that is being developed to support early detection of pressure injuries (PI) to the skin and underlying tissue. DiaSafe is a handheld optical monitoring device that is being developed to support early detection of DFUs in lower limb skin and underlying tissue. Nobiotics is an otoscope designed to support physicians with an immediate indication as to whether a mid-ear infection (otitis media) is of a bacterial origin.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
IR-MED INC.	-13.04%	69.98M
ABBOTT LABORATORIES	-7.16%	178B
MEDTRONIC PLC	-1.23%	107B
BECTON, DICKINSON AND COMPANY	-4.86%	67.04B
DEXCOM, INC.	-4.28%	47.23B
CENCORA, INC.	+10.32%	44.62B
HOYA CORPORATION	+9.25%	42.5B
TERUMO CORPORATION	+15.97%	25.22B
WEST PHARMACEUTICAL SERVICES, INC.	-5.88%	24.14B
ZIMMER BIOMET HOLDINGS, INC.	-5.38%	23.69B

Other Medical Equipment, Supplies & Distribution

IR-Med Inc.

Equities

IRME

US46265R1032

Medical Equipment, Supplies & Distribution

IR-Med Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

Latest news about IR-Med Inc.

Chart IR-Med Inc.

Company Profile

Income Statement Evolution

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Medical Equipment, Supplies & Distribution